The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

(2014) M. A. Dimopoulos et al.   HAEMATOLOGICA

Autoantibodies from long-lived ‘memory’ plasma cells of NZB/W mice drive immune complex nephritis

(2013) Qingyu Cheng et al.   ANNALS OF THE RHEUMATIC DISEASES

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

(2013) M. Wang et al.   BLOOD

Carfilzomib

(2013) K. M. Kortuem et al.   BLOOD

Immunopathogenic mechanisms of systemic autoimmune disease

(2013) Marie Wahren-Herlenius et al.   LANCET

IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus

(2012) Thomas Rose et al.   ANNALS OF THE RHEUMATIC DISEASES

Proteasome inhibitors in multiple myeloma: 10 years later

(2012) P. Moreau et al.   BLOOD

Proteasome inhibitor-based therapy for antibody-mediated rejection

(2012) R. Carlin Walsh et al.   KIDNEY INTERNATIONAL

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells

(2011) H. Travis Ichikawa et al.   ARTHRITIS AND RHEUMATISM

Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE

(2011) Matthew M. Seavey et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Long-lived autoreactive plasma cells drive persistent autoimmune inflammation

(2011) Falk Hiepe et al.   Nature Reviews Rheumatology

Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis

(2010) M. Hirai et al.   BLOOD

Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus

(2008) Robert Biesen et al.   ARTHRITIS AND RHEUMATISM

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

(2008) Kirsten Neubert et al.   NATURE MEDICINE

Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection

(2008) Matthew J. Everly et al.   TRANSPLANTATION